Gamunex® 10%, 100 mg / ml, solution for infusion

Comprehensive Therapeutic Indications for Immunodeficiency and Immunomodulation

Replacement therapy in adults, children and adolescents (0-18 years) in:

Primary immunodeficiency syndromes (PID) with impaired antibody production
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of serum IgG level of level of <4 g/l *PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.
Measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years) in whom active
immunisation is contraindicated or not advised.
Consideration should also be given to official recommendations on intravenous human immunoglobulin use in measles
Pre-/post exposure prophylaxis and active immunisation.

Immunomodulation in adults, children and adolescents (0-18 years) in:

Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
Guillain Barré syndrome
Kawasaki disease (in conjunction with acetylsalicylic acid, see 4.2)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Multifocal motor neuropathy (MMN) Immunomodulation in adults aged ≥18 years in:
Severe acute exacerbations of myasthenia gravis

For more information, please contact us or see the link below: